Pericardial fluid and serum levels of vascular endothelial growth factor and endostatin in patients with or without coronary artery disease

Jer Young Liou, Kou Gi Shyu, Ming Jen Lu, Hung Hsin Chao, Bao Wei Wang, Pei Liang Kuan

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background/Purpose: Vascular endothelial growth factor (VEGF) and endostatin are related to ischemic heart disease. This study investigated pericardial fluid and serum levels of VEGF and endostatin in patients with or without ischemic heart disease. Methods: A total of 39 patients (24 patients in the CAD group with significant coronary artery disease; 15 patients in the non-CAD group without coronary artery disease) undergoing open heart surgery were enrolled. In the CAD group, patients were classified according to good coronary collateralization (Group A; n = 11) or poor coronary collateralization (Group B; n = 13). Pericardial fluid and serum samples were obtained at the time of surgery. VEGF and endostatin were measured by enzyme-linked immunosorbent assay. Results: The levels of endostatin in both serum and pericardial fluid were significantly lower in the CAD group than in the non-CAD group (130.5 ± 37.3 ng/mL vs. 172.4 ± 37.8 ng/mL and 119.0 ± 25.0 ng/mL vs. 143.0 ± 23.5 ng/mL). The concentration of serum VEGF in the CAD group (92.6 ± 18.2 pg/mL) was significantly higher than that in the non-CAD group (75.2 ± 22.3 pg/mL). The concentration of serum VEGF in Group A (100.1 ± 20.7 pg/mL) was significantly higher than that in Group B (84.3 ± 12.4 pg/mL). The levels of pericardial fluid VEGF, serum and pericardial fluid endostatin were not significantly different between Groups A and B. Conclusion: Patients with coronary artery disease have lower serum and pericardial fluid levels of endostatin and higher serum levels of VEGF. Serum level VEGF, but not endostatin, is associated with good or poor collateralization in patients with coronary artery disease.

Original languageEnglish
Pages (from-to)377-383
Number of pages7
JournalJournal of the Formosan Medical Association
Volume105
Issue number5
Publication statusPublished - May 2006

Fingerprint

Endostatins
Vascular Endothelial Growth Factor A
Coronary Artery Disease
Serum
Myocardial Ischemia
Pericardial Fluid
Thoracic Surgery
Enzyme-Linked Immunosorbent Assay

Keywords

  • Collateral circulation
  • Coronary artery disease
  • Endostatin
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pericardial fluid and serum levels of vascular endothelial growth factor and endostatin in patients with or without coronary artery disease. / Liou, Jer Young; Shyu, Kou Gi; Lu, Ming Jen; Chao, Hung Hsin; Wang, Bao Wei; Kuan, Pei Liang.

In: Journal of the Formosan Medical Association, Vol. 105, No. 5, 05.2006, p. 377-383.

Research output: Contribution to journalArticle

Liou, Jer Young ; Shyu, Kou Gi ; Lu, Ming Jen ; Chao, Hung Hsin ; Wang, Bao Wei ; Kuan, Pei Liang. / Pericardial fluid and serum levels of vascular endothelial growth factor and endostatin in patients with or without coronary artery disease. In: Journal of the Formosan Medical Association. 2006 ; Vol. 105, No. 5. pp. 377-383.
@article{ae9ab4c9e044467293e7ab0826fc9489,
title = "Pericardial fluid and serum levels of vascular endothelial growth factor and endostatin in patients with or without coronary artery disease",
abstract = "Background/Purpose: Vascular endothelial growth factor (VEGF) and endostatin are related to ischemic heart disease. This study investigated pericardial fluid and serum levels of VEGF and endostatin in patients with or without ischemic heart disease. Methods: A total of 39 patients (24 patients in the CAD group with significant coronary artery disease; 15 patients in the non-CAD group without coronary artery disease) undergoing open heart surgery were enrolled. In the CAD group, patients were classified according to good coronary collateralization (Group A; n = 11) or poor coronary collateralization (Group B; n = 13). Pericardial fluid and serum samples were obtained at the time of surgery. VEGF and endostatin were measured by enzyme-linked immunosorbent assay. Results: The levels of endostatin in both serum and pericardial fluid were significantly lower in the CAD group than in the non-CAD group (130.5 ± 37.3 ng/mL vs. 172.4 ± 37.8 ng/mL and 119.0 ± 25.0 ng/mL vs. 143.0 ± 23.5 ng/mL). The concentration of serum VEGF in the CAD group (92.6 ± 18.2 pg/mL) was significantly higher than that in the non-CAD group (75.2 ± 22.3 pg/mL). The concentration of serum VEGF in Group A (100.1 ± 20.7 pg/mL) was significantly higher than that in Group B (84.3 ± 12.4 pg/mL). The levels of pericardial fluid VEGF, serum and pericardial fluid endostatin were not significantly different between Groups A and B. Conclusion: Patients with coronary artery disease have lower serum and pericardial fluid levels of endostatin and higher serum levels of VEGF. Serum level VEGF, but not endostatin, is associated with good or poor collateralization in patients with coronary artery disease.",
keywords = "Collateral circulation, Coronary artery disease, Endostatin, Vascular endothelial growth factor",
author = "Liou, {Jer Young} and Shyu, {Kou Gi} and Lu, {Ming Jen} and Chao, {Hung Hsin} and Wang, {Bao Wei} and Kuan, {Pei Liang}",
year = "2006",
month = "5",
language = "English",
volume = "105",
pages = "377--383",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Pericardial fluid and serum levels of vascular endothelial growth factor and endostatin in patients with or without coronary artery disease

AU - Liou, Jer Young

AU - Shyu, Kou Gi

AU - Lu, Ming Jen

AU - Chao, Hung Hsin

AU - Wang, Bao Wei

AU - Kuan, Pei Liang

PY - 2006/5

Y1 - 2006/5

N2 - Background/Purpose: Vascular endothelial growth factor (VEGF) and endostatin are related to ischemic heart disease. This study investigated pericardial fluid and serum levels of VEGF and endostatin in patients with or without ischemic heart disease. Methods: A total of 39 patients (24 patients in the CAD group with significant coronary artery disease; 15 patients in the non-CAD group without coronary artery disease) undergoing open heart surgery were enrolled. In the CAD group, patients were classified according to good coronary collateralization (Group A; n = 11) or poor coronary collateralization (Group B; n = 13). Pericardial fluid and serum samples were obtained at the time of surgery. VEGF and endostatin were measured by enzyme-linked immunosorbent assay. Results: The levels of endostatin in both serum and pericardial fluid were significantly lower in the CAD group than in the non-CAD group (130.5 ± 37.3 ng/mL vs. 172.4 ± 37.8 ng/mL and 119.0 ± 25.0 ng/mL vs. 143.0 ± 23.5 ng/mL). The concentration of serum VEGF in the CAD group (92.6 ± 18.2 pg/mL) was significantly higher than that in the non-CAD group (75.2 ± 22.3 pg/mL). The concentration of serum VEGF in Group A (100.1 ± 20.7 pg/mL) was significantly higher than that in Group B (84.3 ± 12.4 pg/mL). The levels of pericardial fluid VEGF, serum and pericardial fluid endostatin were not significantly different between Groups A and B. Conclusion: Patients with coronary artery disease have lower serum and pericardial fluid levels of endostatin and higher serum levels of VEGF. Serum level VEGF, but not endostatin, is associated with good or poor collateralization in patients with coronary artery disease.

AB - Background/Purpose: Vascular endothelial growth factor (VEGF) and endostatin are related to ischemic heart disease. This study investigated pericardial fluid and serum levels of VEGF and endostatin in patients with or without ischemic heart disease. Methods: A total of 39 patients (24 patients in the CAD group with significant coronary artery disease; 15 patients in the non-CAD group without coronary artery disease) undergoing open heart surgery were enrolled. In the CAD group, patients were classified according to good coronary collateralization (Group A; n = 11) or poor coronary collateralization (Group B; n = 13). Pericardial fluid and serum samples were obtained at the time of surgery. VEGF and endostatin were measured by enzyme-linked immunosorbent assay. Results: The levels of endostatin in both serum and pericardial fluid were significantly lower in the CAD group than in the non-CAD group (130.5 ± 37.3 ng/mL vs. 172.4 ± 37.8 ng/mL and 119.0 ± 25.0 ng/mL vs. 143.0 ± 23.5 ng/mL). The concentration of serum VEGF in the CAD group (92.6 ± 18.2 pg/mL) was significantly higher than that in the non-CAD group (75.2 ± 22.3 pg/mL). The concentration of serum VEGF in Group A (100.1 ± 20.7 pg/mL) was significantly higher than that in Group B (84.3 ± 12.4 pg/mL). The levels of pericardial fluid VEGF, serum and pericardial fluid endostatin were not significantly different between Groups A and B. Conclusion: Patients with coronary artery disease have lower serum and pericardial fluid levels of endostatin and higher serum levels of VEGF. Serum level VEGF, but not endostatin, is associated with good or poor collateralization in patients with coronary artery disease.

KW - Collateral circulation

KW - Coronary artery disease

KW - Endostatin

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=33645931644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645931644&partnerID=8YFLogxK

M3 - Article

C2 - 16638647

AN - SCOPUS:33645931644

VL - 105

SP - 377

EP - 383

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 5

ER -